HCA Healthcare, Inc.
$140.16B- Market cap
- $94.71B
- Debt
- +$46.49B
- Cash
- −$1.04B
Capital structure 67% equity / 33% debt · EV / Revenue 1.85x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: HCA stock price near parity vs INFY $426.94 current versus $412.65 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at INFY's multiple
Implied fair value · at HCA's multiple
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 67% equity / 33% debt · EV / Revenue 1.85x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HCA Healthcare, Inc. · implied price per share
Bear
$171.11
Base
$241.68
Bull
$336.89
INFOSYS LIMITED · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
HCA vs LH
WEST PHARMACEUTICAL SERVICES INC
HCA vs WST
BAXTER INTERNATIONAL INC
HCA vs BAX
MCKESSON CORP
HCA vs MCK
Cigna Group
HCA vs CI
UNITEDHEALTH GROUP INC
HCA vs UNH
Accenture plc
HCA vs ACN
COGNIZANT TECHNOLOGY SOLUTIONS CORP
HCA vs CTSH
INTERNATIONAL BUSINESS MACHINES CORP
HCA vs IBM
DXC Technology Co
HCA vs DXC
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HCA will continue to grow revenue faster than INFY while sustaining a materially higher EBITDA margin, then HCA looks like a reasonable hold to modest buy because its valuation is already near fair value and its balance sheet appears stronger than INFY’s.
HCA’s current price of $410.50 is only 1.3% below the P/E-implied value of $416.00, so the stock is effectively at fair value on this basis. Versus INFY, HCA looks cheaper on enterprise and sales multiples but not on earnings multiples, which suggests the gap is more about business model and margin structure than a clear mispricing.
Supporting Metrics